Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program
Christine Robin(Université Paris-Est Créteil), Catherine Cordonnier(Leiden University Medical Center), Maud D’Aveni(Centre Hospitalier Régional et Universitaire de Nancy), Stéphanie Nguyen‐Quoc(Sorbonne Université), Rabah Redjoul(Assistance Publique – Hôpitaux de Paris), Nathalie Bénard(MSD (France)), Anne Thiébaut(Centre Hospitalier Universitaire de Grenoble), Flore Sicre de Fontbrune(Assistance Publique – Hôpitaux de Paris), Sophie Alain(Université de Limoges), Ana Berceanu(Centre Hospitalier Universitaire de Besançon), Patrice Céballos(Hôpital Saint Eloi), Golriz Pahlavan-Grumel(MSD (France))
Cited by 77
Related Papers
Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy
|The Lancet Infectious Diseases|2017|822
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299
Bacterial Populations Contaminating The Upper Gut in Patients With Small Intestinal Bacterial Overgrowth Syndrome
|The American Journal of Gastroenterology|1999|196
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients
|Journal of the American Society of Nephrology|2021|185